AlphaTON Capital (ATON) Q2 2025 earnings summary

Executive summary

• Net loss for the quarter ended September 30, 2024 was $1.4 million, a significant improvement from $5.2 million in the same quarter last year.

• Operating expenses dropped to $1.6 million from $5.9 million year-over-year, reflecting reduced R&D and G&A costs.

• Strategic alternatives under consideration include asset partnerships, sale, merger, restructuring, wind down, or further financing.

• Clinical trial activity has been paused or discontinued due to financial constraints, notably the ADPORT-601 and iNKT programs.

Financial highlights

• R&D expenses decreased by 83% to $0.7 million, mainly due to winding down clinical and manufacturing activities.

• G&A expenses fell by 48% to $0.9 million, driven by lower professional fees, payroll, and waived directors' fees.

• Net gain of $0.9 million from settlement with Parexel, offset by a $0.7 million non-cash loss from warrant liability revaluation.

• Cash and cash equivalents stood at $1.8 million as of September 30, 2024, with current liabilities of $0.9 million.

• Basic and diluted loss per share was $1.26, compared to $5.80 in the prior year quarter.

Outlook and guidance

• Exploration of strategic alternatives continues, including potential partnerships, sale, merger, restructuring, or wind down.

• Further patient accrual in the ADPORT-601 trial remains paused pending additional financial resources.